| In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl … NA Tatton, SJ Kish Neuroscience 77 (4), 1037-1048, 1997 | 612 | 1997 |
| Apoptosis in Parkinson's disease: signals for neuronal degradation WG Tatton, R Chalmers‐Redman, D Brown, N Tatton Annals of Neurology: Official Journal of the American Neurological …, 2003 | 508 | 2003 |
| Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease NA Tatton Experimental neurology 166 (1), 29-43, 2000 | 487 | 2000 |
| A fluorescent double‐labeling method to detect and confirm apoptotic nuclei in Parkinson's disease NA Tatton, A Maclean‐Fraser, WG Tatton, DP Perl, CO Warren Annals of neurology 44 (S1 1), S142-S148, 1998 | 280 | 1998 |
| Spatial distribution of Bax and Bcl‐2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation? O Verborgt, NA Tatton, RJ Majeska, MB Schaffler Journal of bone and mineral research 17 (5), 907-914, 2002 | 244 | 2002 |
| Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer GW Carlile, RME Chalmers-Redman, NA Tatton, A Pong, KLB Borden, ... Molecular pharmacology 57 (1), 2-12, 2000 | 220 | 2000 |
| Dopaminergic neurons degenerate by apoptosis in Parkinson's disease EC Hirsch, S Hunot, B Faucheux, Y Agid, Y Mizuno, H Mochizuki, ... Movement disorders: official journal of the Movement Disorder Society 14 (2 …, 1999 | 188 | 1999 |
| Propargylamines induce antiapoptotic new protein synthesis in serum-and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells WG Tatton, RME Chalmers-Redman, WJH Ju, M Mammen, GW Carlile, ... Journal of Pharmacology and Experimental Therapeutics 301 (2), 753-764, 2002 | 181 | 2002 |
| Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP NA Seniuk, WG Tatton, CE Greenwood Brain research 527 (1), 7-20, 1990 | 170 | 1990 |
| Neuroprotection by deprenyl and other propargylamines: glyceraldehyde-3-phosphate dehydrogenase rather than monoamine oxidase B W Tatton, R Chalmers-Redman, N Tatton Journal of neural transmission 110, 509-515, 2003 | 154 | 2003 |
| Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. JT Henderson, NA Seniuk, PM Richardson, J Gauldie, JC Roder The Journal of clinical investigation 93 (6), 2632-2638, 1994 | 146 | 1994 |
| Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling WG Tatton, RME Chalmers-Redman, M Elstner, W Leesch, ... Advances in Research on Neurodegeneration, 77-100, 2000 | 135 | 2000 |
| Increased CNTF gene expression in process‐bearing astrocytes following injury is augmented by R (−)‐deprenyl NA Seniuk, JT Henderson, WG Tatton, JC Roder Journal of neuroscience research 37 (2), 278-286, 1994 | 118 | 1994 |
| (−)-Deprenyl reduces neuronal apoptosis and facilitates neuronal outgrowth by altering protein synthesis without inhibiting monoamine oxidase WG Tatton, JS Wadia, WYH Ju, RME Chalmers-Redman, NA Tatton Deprenyl—Past and Future: Journal of Neural Transmission Supplement 48, 45-59, 1996 | 116 | 1996 |
| The social and economic burden of frontotemporal degeneration JE Galvin, DH Howard, SS Denny, S Dickinson, N Tatton Neurology 89 (20), 2049-2056, 2017 | 115 | 2017 |
| MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells WG Tatton, MM Kwan, MC Verrier, NA Seniuk, E Theriault Brain research 527 (1), 21-31, 1990 | 109 | 1990 |
| Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription WG Tatton, RME Chalmers-Redman, WYH Ju, J Wadia, NA Tatton Advances in Research on Neurodegeneration: 3 & 4, 245-268, 1997 | 107 | 1997 |
| Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation W Tatton, D Chen, R Chalmers-Redman, L Wheeler, R Nixon, N Tatton Survey of ophthalmology 48 (2), S25-S37, 2003 | 103 | 2003 |
| Utility of the global CDR® plus NACC FTLD rating and development of scoring rules: Data from the ARTFL/LEFFTDS Consortium T Miyagawa, D Brushaber, J Syrjanen, W Kremers, J Fields, LK Forsberg, ... Alzheimer's & Dementia 16 (1), 106-117, 2020 | 93 | 2020 |
| Progranulin as a therapeutic target in neurodegenerative diseases H Rhinn, N Tatton, S McCaughey, M Kurnellas, A Rosenthal Trends in Pharmacological Sciences 43 (8), 641-652, 2022 | 91 | 2022 |
